Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples